FDA Inspection 1264015 — Shandong Anxin Pharmaceutical Co., Ltd. (Laoling Site)
The FDA completed an inspection of Shandong Anxin Pharmaceutical Co., Ltd. (Laoling Site) on Mar 14, 2025 in Dezhou. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Mar 14, 2025
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Dezhou (China)